Cancer Studies

Actos Studies, Actos Related Bladder Cancer Lawsuits, Actos Lawsuits

Epidemiological studies of the side effects associated with Actos have been conducted or are on going in the U.S. and Europe.

Takeda Pharmaceutical Co., the maker of Actos® (pioglitazone), began an extensive ten-year in 2002, monitoring more than 193,000 patients. In September of 2010, the FDA announced a safety review of the preliminary findings in the Takeda study. The FDA’s subsequent analysis revealed a 40 percent increase in risk of bladder cancer in patients taking the drug longer than a year.

Used to treat type 2 diabetes, Actos® is designed to control blood sugar. The drug is sold alone or in combination with Actoplus Met, Actoplus Met XR and Duetact. In 2010, more than 2 million patients in the U. S. were taking these drugs, according to the FDA.

Actos® Resource Links

Below are links related to Actos® safety announcements and news stories.

U.S. Food and Drug Administration

FDA Drug Safety Communication

August 4, 2011 FDA Drug Safety

June 15, 2011 FDA Drug Safety

Cohort Study of Pioglitazone and Cancer Incidence in Patients with Diabetes

New England Journal of Medicine – Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

SpringerLink – a collection of articles on pharmacotherapy of diabetes and cancer risk

Health News

Web MD

Contact an Experienced Attorney to Pursue Justice

The law firm of Rudolph F.X. Migliore, P.C. is investigating potential Actos® lawsuits, with co-counsel for clients nationwide. If you or a loved one has taken Actos® and has developed bladder cancer, take advantage of our firm’s free case evaluation. Call our law firm today at (631) 543-3663 or use our contact form.

Find out if you are entitled to compensation for the harm you suffered. We take Actos®cases on a contingency basis. There is no fee unless we recover damages on your behalf.

Contact Our Firm

Navigation